CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that it has been issued a patent from the U.S. Patent and Trademark Office (USPTO) covering the use of aldoxorubicin intravenously, intra-arterially or intramuscularly for the treatment of brain cancer, which patent was exclusively licensed by CytRx to NantCell, Inc. in July 2017. The new patent issued on May 7, 2019 as U.S. Patent No. 10,278,981, is titled “Cytotoxic Agents for The Treatment of Cancer.”
“We are continually impressed with the progress that our partner and licensee NantCell has made with advancing aldoxorubicin in high unmet need oncology indications,” said Eric Curtis, CytRx’s President and Chief Operating Officer. “As NantCell continues to produce promising combination data in disease areas such as triple negative breast cancer, head and neck squamous cell carcinoma and recurrent metastatic pancreatic cancer, we are pleased to see that they are committed to exploring the drug’s utility in other disease areas such as colorectal cancer, and now potentially brain cancer, where we believe may transform the treatment paradigm for patients. We look forward to seeing NantCell’s further progress with the growing list of aldoxorubicin applications.”
